Skip to main content
Morbidity and Mortality Weekly Report logoLink to Morbidity and Mortality Weekly Report
. 2021 Jan 29;70(4):144. doi: 10.15585/mmwr.mm7004a5

Erratum: Vol. 69, No. 50

PMCID: PMC7842818

In the report “The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020,” on page 1922, in the third paragraph, the third and fourth sentences should have read Consistent high efficacy (≥92%) was observed across age, sex, race, and ethnicity categories and among persons with underlying medical conditions. Efficacy was similarly high in a secondary analysis including participants both with or without evidence of previous SARS-CoV-2 infection. Although numbers of observed hospitalizations and deaths were low, the available data were consistent with reduced risk for these severe outcomes among vaccinated persons compared with that among placebo recipients.


Articles from Morbidity and Mortality Weekly Report are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES